Clinical Trials

240 enrolled

Advanced Solid Tumors

NCT05579366 2026-06-03

RAINFOL-01

BreastGynecologicOther solid neoplasmThoracic

884 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07469774 2026-05-28

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

111 enrolled

Locally Advanced or Metastatic Solid Tumors

NCT07095868 2026-05-27

Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors

94 enrolled

Selected Types of Solid Tumor

NCT05067283 2026-05-26

KANDLELIT-001

830 enrolled

Advanced Solid Tumors

NCT06462794 2026-05-15

First In Human Study of CX-801 in Advanced Solid Tumors

121 enrolled

Solid Tumor, Adult

NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Phase 2 Recruiting

170 enrolled

Solid Tumors

NCT05901285 2026-05-14

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

48 enrolled

Advanced Solid Tumor

NCT07182591 2026-05-14

A Study of DS5361b in Participants With Advanced Solid Tumors

192 enrolled

Other solid neoplasmThoracic

Advanced Solid Tumor

NCT07098988 2026-05-13

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

Phase 2 Recruiting

107 enrolled

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06795412 2026-05-04

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

220 enrolled

Advanced Solid Tumors

NCT05732831 2026-04-21

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

GastrointestinalOther solid neoplasmSarcomaThoracic

225 enrolled

Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT07204340 2026-04-21

TLN-372 in Advanced KRAS Mutant Solid Tumors

240 enrolled

KRAS Mutant Solid Tumors

NCT06576037 2026-04-16

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

128 enrolled

Solid Tumor

NCT04219254 2026-04-15

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

197 enrolled

Solid Tumor, Adult

NCT06960395 2026-04-13

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

450 enrolled

Solid Tumor Malignancies

NCT05101070 2026-03-18

aCCeleR8-001

282 enrolled

Solid Tumors

NCT06234397 2026-03-11

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

245 enrolled

Advanced or Metastatic Solid Tumors

NCT06994806 2026-03-03

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

84 enrolled

Solid Tumor Malignancies

NCT05701527 2026-02-05

A Study of EBC-129 in Advanced Solid Tumours

98 enrolled

Advanced Solid Tumours

NCT07215637 2026-02-02

Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors

60 enrolled

Advanced Solid Tumors

NCT06302426 2026-01-16

Trial of INI-4001 in Patients With Advanced Solid Tumours

50 enrolled

Advanced Solid Tumor

NCT07231458 2026-01-16

A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

27 enrolled

Advanced Solid Tumors

NCT05405595 2026-01-07

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

186 enrolled

Advanced/Metastatic Solid Tumors

NCT06724016 2025-12-17

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

292 enrolled

Advanced or Metastatic Solid Tumors

NCT03556228 2025-12-11

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

GastrointestinalHead & NeckOther solid neoplasmThoracic

242 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Head and Neck Neoplasms, Laryngeal Diseases, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Salivary Gland Neoplasms, Tracheal Diseases, Small Cell Lung Carcinoma

NCT07174453 2025-12-08

Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

Phase 3 Recruiting

192 enrolled

Solid Tumor Malignancies

NCT03760575 2025-12-04

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Other solid neoplasmThoracic

20 enrolled

Mesothelioma, Malignant

NCT05547321 2025-11-25

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

150 enrolled

Advanced Solid Tumor

NCT07123415 2025-11-19

A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

110 enrolled

Advanced Solid Cancer

NCT07158918 2025-09-08

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

65 enrolled

Solid Tumors

NCT05761223 2025-08-17

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

151 enrolled

Advanced Solid Tumor

NCT05978102 2025-07-23

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

183 enrolled

Advanced Solid Tumor

NCT06719362 2025-07-10

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

110 enrolled

Advanced Solid Tumors

NCT05086692 2025-07-09

ABILITY-1